Sarah Stamler

Dr. Sarah Stamler


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Radiology
Verified
Journal Article
Closed access
JSJanice S. Sung
Janice S. Sung
SSSarah Stamler
Sarah Stamler
JBJennifer Brooks
Jennifer Brooks
JKJennifer Kaplan
Jennifer Kaplan
THTammy Huang
Tammy Huang
CCChristopher E. Comstock
Christopher E. Comstock
In a screening program combining annual MR imaging and mammography in women at high risk of cancer, invasive cancer was more likely to be detected at breast MR imaging, 28 of 43(65%) cancers detect... PurposeTo compare the clinical, imaging, and histopathologic features of breast cancers detected at screening magnetic resonance (MR) imaging, screening mammography, and those detected between scre...

12 March 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
NMNet, Miguel Jose M.
Net, Miguel Jose M.
AHAntoine Hamedi-Sangsari
Antoine Hamedi-Sangsari
TSTaylor Schwartz
Taylor Schwartz
MBMirelys Barrios
Mirelys Barrios
NBNicole Brofman
Nicole Brofman
MYMonica Yepes
Monica Yepes
Background: Synthetic 2D mammography was developed to decrease radiation exposure, but to our knowledge there have been no studies evaluating the impact of implementation of full field synthetic mammography/digital breast tomosynthesis (FFSM/DBT) on indications for stereotactic biopsy. Objective: To compare indications and biopsy outcomes for stereotactic biopsy for full field digital mammography (FFDM/DBT) to those of FFSM/DBT. Methods: Retrospective chart review of stereotactic biopsies performed from July 2014 to September 2018. Reports were reviewed and indication for biopsy, lesion size, and final pathology were recorded. Comparison between the two groups following transition to FFSM/DBT in 2016 was performed. Results: 66 of 361 stereotactic biopsies performed in the FFDM/DBT group were malignant (PPV 18.3%), compared to 60 of the 391 biopsies performed in the FFSM/DBT group (PPV 15.4%) with no significant difference in PPV (p = 0.281). There were statistically significant changes in indications for biopsies after transitioning to FFSM/DBT: with a decrease in calcifications referred for biopsy (68.03% vs. 89.75%; p < 0.001), and a statistically significant increase in referral of masses (10.74% vs. 4.43%; p < 0.001), asymmetries (15.60% vs. 5.26%; p < 0.001), and architectural distortion (5.63% vs. 0.55%; p < 0.001). PPV across all indications (21.8% in FFSM/DBT vs. 20.3% in FFDM; p = 0.213), and invasive cancer yield (5.63% vs. 3.32%; p = 0.129) remained comparable following transition to FFSM/DBT without statistically significant differences. Conclusions: Following transition to FFSM/DBT, statistically significant shifts in indications for biopsies were observed with a decrease in referral of calcifications and an increase for masses, asymmetries and architectural distortions. PPV for stereotactic biopsy was not significantly different and cancer yield across all indications remained similar, with an increase in invasive cancer diagnosis.